Vascular Biogenics (NASDAQ:VBLT) Stock Rating Lowered by Zacks Investment Research

Vascular Biogenics (NASDAQ:VBLT) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a note issued to investors on Thursday, Zacks.com reports.

According to Zacks, “Vascular Biogenics Ltd. is a clinical stage biotechnology company. It is focused on the discovery, development and commercialization of treatments for cancer and immune-inflammatory diseases. Its lead oncology candidate VB-111, is a gene-based biologic which is in Phase II clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer. It is also developing VB-201, an oral small molecule that is in Phase II clinical trials for the treatment psoriasis and ulcerative colitis. Vascular Biogenics Ltd. is headquartered in Or Yehuda, Israel. “

Separately, HC Wainwright restated a “buy” rating and issued a $4.00 price target on shares of Vascular Biogenics in a report on Tuesday, November 16th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $5.10.

Shares of Vascular Biogenics stock opened at $2.20 on Thursday. Vascular Biogenics has a 1 year low of $1.18 and a 1 year high of $3.17. The firm’s 50-day moving average is $2.23 and its two-hundred day moving average is $2.26. The stock has a market cap of $137.21 million, a price-to-earnings ratio of -4.31 and a beta of 1.11.

Vascular Biogenics (NASDAQ:VBLT) last released its quarterly earnings results on Monday, November 15th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.02. Vascular Biogenics had a negative net margin of 3,546.69% and a negative return on equity of 69.23%. During the same period in the previous year, the company posted ($0.12) EPS. Research analysts predict that Vascular Biogenics will post -0.44 earnings per share for the current year.

A number of hedge funds have recently added to or reduced their stakes in VBLT. Two Sigma Advisers LP acquired a new stake in Vascular Biogenics in the 3rd quarter worth approximately $30,000. Goldman Sachs Group Inc. boosted its stake in Vascular Biogenics by 44.1% in the 2nd quarter. Goldman Sachs Group Inc. now owns 16,556 shares of the biopharmaceutical company’s stock worth $40,000 after purchasing an additional 5,069 shares in the last quarter. Jane Street Group LLC acquired a new stake in Vascular Biogenics in the 3rd quarter worth approximately $42,000. Geode Capital Management LLC boosted its stake in Vascular Biogenics by 62.1% in the 3rd quarter. Geode Capital Management LLC now owns 40,323 shares of the biopharmaceutical company’s stock worth $82,000 after purchasing an additional 15,450 shares in the last quarter. Finally, Millennium Management LLC acquired a new stake in Vascular Biogenics in the 2nd quarter worth approximately $89,000. Institutional investors own 6.15% of the company’s stock.

About Vascular Biogenics

Vascular Biogenics Ltd. is in the clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of first-in-class treatments for cancer. Its programs include cancer, inflammation, and VB-600 which are focused on treating tumors, ovarian cancer, and chronic immune-related indications.

See Also: Trading Options- What is a Strangle?

Get a free copy of the Zacks research report on Vascular Biogenics (VBLT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Vascular Biogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics and related companies with MarketBeat.com's FREE daily email newsletter.